Skip to content

Longevity Drug Index / GLP-1 drugs

Rank 2 of 10Fastest-rising candidate; healthy-human trial under way

GLP-1 drugs

Weight-loss and diabetes medicines whose benefits for the heart, kidneys and inflammation have made them a serious longevity candidate.

Rank
2 of 10
Drug class
GLP-1 and GIP receptor agonists
Approved for
Type 2 diabetes and obesity
Also known as
Semaglutide, tirzepatide

More on Peptide Analysis: GLP-1 Performance Index · Semaglutide · Tirzepatide

How it works

These drugs mimic gut hormones released after a meal. They boost insulin when blood sugar is high, lower glucagon, slow stomach emptying and act on appetite centres in the brain, so people eat less. Semaglutide acts on the GLP-1 receptor; tirzepatide acts on both the GLP-1 and GIP receptors. The receptors are also found in the heart, blood vessels, kidneys and immune cells.

How it could help longevity

Obesity, diabetes, heart disease and kidney disease are among the biggest drivers of age-related illness and death, and these drugs reduce all of them. Some benefits appear before much weight is lost, which suggests direct effects on inflammation and blood vessels. They are also being studied for liver disease, sleep apnoea and addiction.

Animal studies

  • Late-life semaglutide in female mice (Nature, September 2026)A UC Berkeley team gave semaglutide to 20-month-old female mice, roughly 60 in human years, for the rest of their lives. Median lifespan rose from 742 to 834 days, about 12% longer. The benefits overlapped with those of a 24% calorie-restricted diet, but treated mice also did better on memory and blood sugar control, which suggests partly separate mechanisms. It is the first strong lifespan result for this drug class.
  • Organ protectionMany animal studies show GLP-1 drugs reduce inflammation and protect the heart, kidneys, liver and blood vessels, partly independently of weight loss.

Human studies

  • SELECT trial, 2023In 17,604 adults with overweight or obesity and heart disease but no diabetes, semaglutide cut heart attacks, strokes and cardiovascular deaths by 20% compared with placebo.
  • FLOW trial, 2024In people with type 2 diabetes and chronic kidney disease, semaglutide reduced serious kidney outcomes and death by 24%.
  • Novo Nordisk aging clocks (October 2026)Novo analysed blood proteins from 10,052 people in five placebo-controlled semaglutide trials. On protein-based aging clocks, the heart looked about 2 to 4 years younger than on placebo, with smaller gains of 1 to 4 years for the kidney, brain and other organs; Novo summarises the overall effect as 2 to 3 years. The results were presented at the ARDD 2026 aging conference, reported by MIT Technology Review, and posted as a preprint that has not yet been peer-reviewed. The authors stress it does not prove the drug reverses aging.
  • Eli Lilly aging clocks (October 2026)Lilly measured DNA-based (epigenetic) clocks in 71 people taking tirzepatide in the SURMOUNT-5 trial. Over 72 weeks, all 15 clocks advanced less than calendar time, but only two reached statistical significance. There was no placebo group, so Lilly describes it as an early pilot.
  • HIV trial, 2025In a small randomised trial in people with HIV-related fat build-up, semaglutide slowed several epigenetic aging clocks compared with placebo.
  • What experts saySteve Horvath (UCLA), who pioneered aging clocks, called a two-year effect strong but said there is not yet enough evidence the drugs help people without obesity. Vadim Gladyshev (Harvard), who worked with Novo, said that in a healthy population no one knows yet. All the clock data so far come from overweight, diabetic or HIV patients.
  • Trials in healthy older adultsVITAL-H, a placebo-controlled trial led by UT Health San Antonio with up to $38 million from the US agency ARPA-H, will test semaglutide, rapamycin and dapagliflozin in adults in their 60s. A separate placebo-controlled trial at UTMB is testing tirzepatide on aging clocks in adults aged 55 to 70.
  • LimitsOral semaglutide did not slow decline in early Alzheimer’s disease in the large EVOKE trials, a reminder that the benefits are not universal.

Safety and side effects

Nausea, vomiting, diarrhoea and constipation are common, especially when the dose is increased. Gallbladder problems and, rarely, pancreatitis can occur. Muscle is lost along with fat, and most weight returns when treatment stops. They are not used in people with a personal or family history of medullary thyroid cancer.

Our view

No other candidate has such large, placebo-controlled human trials showing fewer deaths and less disease, and the first aging-clock data and a strong mouse lifespan study point the same way. The open question is whether the benefit goes beyond treating obesity and diabetes, which only trials in healthy, normal-weight people such as VITAL-H can answer.

Last reviewed 11 November 2026. General information, not medical advice. None of these drugs is approved to slow aging.